Free Flow, Inc. Announces Strategic Acquisition Move
Free Flow, Inc. (FFLO), which operates under the name Free Flow USA, Inc. in Delaware, is making significant progress in its strategic initiatives. The company has entered into a Letter of Intent (LOI) to acquire an over-the-counter pharmaceutical wholesaler and contract manufacturer. This target company generated gross revenues of $4.4 million last year and is expected to bring in around $7 million in revenue for the current year.
Details of the Acquisition
With this acquisition, the targeted company will become a wholly-owned subsidiary of Free Flow. This strategic move is set to become a key focus of the company’s operations, alongside potential future acquisitions in the pharmaceutical industry. Additionally, Free Flow is looking into acquiring another company that has annual sales exceeding $70 million.
Financial and Regulatory Considerations
The LOI requires an independent business valuation and audit to be conducted in accordance with Securities and Exchange Commission regulations. This process is anticipated to take approximately 90 days, though there are provisions for extensions to ensure comprehensive due diligence.
Implications for Customer Base
The initial acquisition target is reported to have a well-established customer base that includes over twenty pharmaceutical, food, drug, and mass retailers. More information regarding the acquisition and the specific nature of its operations will be disclosed as the closing date approaches.
Leadership Changes at Free Flow
In line with the company’s evolving focus, Free Flow has appointed Dr. Ravinder Tikoo, a board-certified neurologist, as the new chairman of the board. This leadership change will allow Dr. Tikoo to provide valuable insights as the company navigates its new business direction. CEO Sabir Saleem and independent director Shah Wali Khan will continue to play essential roles on the board, working closely with Dr. Tikoo.
Background of Dr. Ravinder Tikoo
Dr. Tikoo boasts an impressive academic and professional background, holding a BS in Chemistry and Biochemistry from the University of Iowa, where he also earned his medical degree in 1991. His medical expertise is further underscored by internships and fellowships in neurology at prestigious institutions, making him a significant asset for Free Flow as the company expands into the pharmaceutical sector.
Future Outlook for Free Flow, Inc.
A Current Report on Form 8-K will soon be filed with the Securities and Exchange Commission to detail Dr. Tikoo's appointment. Mr. Saleem expressed excitement about Dr. Tikoo’s role, noting that his extensive medical experience will be crucial in guiding the company through the initial acquisition phase and in identifying further opportunities in the pharmaceutical market.
Corporate Headquarters Update
In addition to these promising developments, Free Flow has amended its Articles of Incorporation to reflect its new name, Free Flow USA, Inc., which took effect recently. The company has also established a new corporate headquarters, signaling a fresh chapter in its operational journey.
About Free Flow, Inc.
Free Flow, Inc. is committed to creating and acquiring subsidiaries with the goal of maximizing shareholder value through sustainable growth. Currently engaged in the scrap metal processing and salvage yard business, the company is strategically pursuing both initial and subsequent acquisitions in the pharmaceutical industry.
Frequently Asked Questions
What is the recent acquisition by Free Flow, Inc.?
Free Flow, Inc. has announced an agreement to acquire a pharmaceutical wholesaler, aiming to expand its operations in the pharmaceutical sector.
Who has been appointed as the new chairman of Free Flow, Inc.?
Dr. Ravinder Tikoo has been appointed as the new chairman of the board at Free Flow, Inc., bringing extensive medical expertise to the leadership team.
What are the projected revenues for the company being acquired?
The target company reported gross revenues of $4.4 million in the prior year and is projected to generate around $7 million in the current year.
What regulatory steps are involved in the acquisition process?
The acquisition process includes an independent business valuation and audit as required by Securities and Exchange Commission regulations, expected to be completed within 90 days.
What is the focus of Free Flow, Inc. moving forward?
Free Flow, Inc. is shifting its focus towards acquiring businesses in the pharmaceutical sector to enhance shareholder value and promote long-term growth.
